Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sirolimus in Treating Patients With Advanced Pancreatic Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: July 10, 2007
Last updated: October 18, 2016
Last verified: October 2016
Results First Received: March 18, 2013  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Pancreatic Cancer
Intervention: Drug: sirolimus

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
During baseline evaluation (approximately 72 hours prior to treatment with rapamycin), patients will receive a single dose of 3 mg oral midazolam as phenotypic evaluation of CYP3A4 activity.

Reporting Groups
Sirolimus Patients with advanced pancreatic adenocarcinoma refractory to gemcitibine received Sirolimus at a single oral flat dose of 5 mg. per day. A treatment cycle was 28 days.

Participant Flow:   Overall Study
STARTED     47  
COMPLETED     31  
Withdrawal by Subject                 16  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All patients had previously progressed to a gemcitabine-containing regimen, including 22 patients who had received previous chemotherapy for metastatic disease.

Reporting Groups
Sirolimus adencarcinoma refractory to gemcitibine

Baseline Measures
Number of Participants  
[units: participants]
[units: participants]
<=18 years     0  
Between 18 and 65 years     25  
>=65 years     22  
[units: participants]
Female     15  
Male     32  
Region of Enrollment  
[units: participants]
United States     47  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Patients With Overall Survival at 6 Months   [ Time Frame: 6- month survival rate (6mSR) ]

2.  Primary:   Response Rate (Complete, Partial Response and Stable Disease) as Assessed by RECIST   [ Time Frame: response at 2 and 6 months ]

3.  Primary:   Severity of Adverse Events as Assessed by NCI CTCAE v3.0   [ Time Frame: 6 months ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dr. Hidalgo
Organization: The Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins

Publications of Results:

Responsible Party: Sidney Kimmel Comprehensive Cancer Center Identifier: NCT00499486     History of Changes
Other Study ID Numbers: JHOC-J0415, CDR0000549899
P30CA006973 ( US NIH Grant/Contract Award Number )
Study First Received: July 10, 2007
Results First Received: March 18, 2013
Last Updated: October 18, 2016
Health Authority: United States: Food and Drug Administration